Background: Inflammatory response state is related to the pathogenesis of gestational diabetes mellitus (GDM). Objective: To investigate the changes of serum sex hormone-binding globulin (SHBG), homocysteine (Hcy), and hypersensitive CRP (hs-CRP) levels during pregnancy and their relationship with GDM. Methods: The nested case-control study method was used. Sixty nonobese single pregnant women diagnosed with GDM were divided into the GDM group (GDM, n = 60), together with another 60 pregnant women with normal glucose tolerance who were matched in the same period and divided into the control group (control, n = 60). The serum Hcy, hs-CRP, and SHBG levels were measured. Results: The serum levels of Hcy and hs-CRP were significantly higher in the GDM group compared with the control group, and serum levels of SHBG was significantly lower in the GDM group compared with the control group at different stages of pregnancy. The serum levels of Hcy and hs-CRP in pregnant women increased with the increase of gestational age, and serum levels of SHBG decreased with the increase of gestational age. Increased Hcy and hs-CRP levels in the second trimester and decreased SHBG levels in the first trimester were related to GDM. The odds ratio (OR) and 95% confidence interval (CI) were as follows: OR: 4.5, 95% CI: 1.5–13.0; OR: 4.2, 95% CI: 1.5–10.1; and OR: 0.4, 95% CI: 0.3–0.7, respectively. Conclusion: Increased Hcy and hs-CRP in the second trimester and decreased SHBG in the first trimester were independent predictors of GDM, which provides a new idea for early prevention and treatment of GDM.

1.
Szmuilowicz
ED
,
Josefson
JL
,
Metzger
BE
.
Gestational diabetes mellitus
.
Endocrinol Metab Clin North Am
.
2019
;
48
(
3
):
479
93
. .
2.
Wang
B
,
Xue
X
.
Investigations of associations between seven gene polymorphisms and gestational diabetes mellitus: evidence from a meta-analysis
.
Gynecol Obstet Invest
.
2020
;
85
(
3
):
229
36
. .
3.
Zhu
Y
,
Zhang
C
.
Prevalence of gestational diabetes and risk of progression to type 2 diabetes: a global perspective
.
Curr Diab Rep
.
2016
;
16
(
1
):
7
. .
4.
Pivari
F
,
Mingione
A
,
Brasacchio
C
,
Soldati
L
.
Curcumin and type 2 diabetes mellitus: prevention and treatment
.
Nutrients
.
2019
;
11
(
8
):
1837
. .
5.
Sattar
N
.
Biomarkers for diabetes prediction, pathogenesis, or pharmacotherapy guidance? Past, present and future possibilities
.
Diabet Med
.
2012
;
29
(
1
):
5
13
.
6.
Mertoglu
C
,
Gunay
M
,
Gungor
M
,
Kulhan
M
,
Kulhan
NG
.
A study of inflammatory markers in gestational diabetes mellitus
.
Gynecol Obstet Reprod Med
.
2018
;
25
:
7
11
. .
7.
Alatab
S
,
Fakhrzadeh
H
,
Sharifi
F
,
Mirarefin
M
,
Badamchizadeh
Z
,
Ghaderpanahi
M
, et al
Correlation of serum homocysteine and previous history of gestational diabetes mellitus
.
J Diabetes Metab Disord
.
2013
;
12
:
34
. .
8.
Mohammed
M
,
Al-Habori
M
,
Abdullateef
A
,
Saif-Ali
R
.
Impact of metabolic syndrome factors on testosterone and SHBG in type 2 diabetes mellitus and metabolic syndrome
.
J Diabetes Res
.
2018
;
2018
:
4926789
. .
9.
Berezin
AE
.
Cardiac biomarkers in diabetes mellitus: new dawn for risk stratification?
Diabetes Metab Syndr
.
2017
;
11
(
Suppl 1
):
S201
8
. .
10.
Yu
N
,
Cui
H
,
Chen
X
,
Chang
Y
.
Changes of serum pentraxin-3 and hypersensitive CRP levels during pregnancy and their relationship with gestational diabetes mellitus
.
PLoS One
.
2019
;
14
(
11
):
e0224739
. .
11.
Pivari
F
,
Mingione
A
,
Brasacchio
C
,
Soldati
L
.
Curcumin and type 2 diabetes mellitus: prevention and treatment
.
Nutrients
.
2019
;
11
(
8
):
1837
. .
12.
Inanli
I
,
Aydin
M
,
Çaliskan
AM
,
Eren
I
.
Neutrophil/lymphocyte ratio, monocyte/lymphocyte ratio, and mean platelet volume as systemic inflammatory markers in different states of bipolar disorder
.
Nord J Psychiatry
.
2019
;
73
(
6
):
372
9
. .
13.
Kumari
R
,
Singh
H
.
The prevalence of elevated high-sensitivity C-reactive protein in normal pregnancy and gestational diabetes mellitus
.
J Family Med Prim Care
.
2017 Apr–Jun
;
6
(
2
):
259
64
. .
14.
Alatab
S
,
Fakhrzadeh
H
,
Sharifi
F
,
Mirarefin
M
,
Badamchizadeh
Z
,
Ghaderpanahi
M
, et al
Correlation of serum homocysteine and previous history of gestational diabetes mellitus
.
J Diabetes Metab Disord
.
2013
;
12
:
34
. .
15.
Gong
T
,
Wang
J
,
Yang
M
,
Shao
Y
,
Liu
J
,
Wu
Q
, et al
Serum homocysteine level and gestational diabetes mellitus: a meta-analysis
.
J Diabetes Investig
.
2016
;
7
(
4
):
622
8
. .
16.
Idzior-Waluś
B
,
Cyganek
K
,
Sztefko
K
,
Seghieri
G
,
Breschi
MC
,
Waluś-Miarka
M
, et al
Total plasma homocysteine correlates in women with gestational diabetes
.
Arch Gynecol Obstet
.
2008
;
278
(
4
):
309
13
. .
17.
Radzicka
S
,
Ziolkowska
K
,
Zaborowski
MP
,
Brazert
J
,
Pietryga
M
.
Serum homocysteine and vitamin B12 levels in women with gestational diabetes mellitus
.
Ginekol Pol
.
2019
;
90
(
7
):
381
7
. .
18.
Ding
VD
,
Moller
DE
,
Feeney
WP
,
Didolkar
V
,
Nakhla
AM
,
Rhodes
L
, et al
Sex hormone-binding globulin mediates prostate androgen receptor action via a novel signaling pathway
.
Endocrinology
.
1998
;
139
(
1
):
213
8
. .
19.
Kaňová
N
,
Bičíková
M
.
Hyperandrogenic states in pregnancy
.
Physiol Res
.
2011
;
60
(
2
):
243
52
.
20.
Zhang
T
,
Du
T
,
Li
W
,
Yang
S
,
Liang
W
.
Sex hormone-binding globulin levels during the first trimester may predict gestational diabetes mellitus development
.
Biomark Med
.
2018
;
12
(
3
):
239
44
. .
21.
Zhang
B
,
Jin
Z
,
Sun
L
,
Zheng
Y
,
Jiang
J
,
Feng
C
, et al
Expression and correlation of sex hormone-binding globulin and insulin signal transduction and glucose transporter proteins in gestational diabetes mellitus placental tissue
.
Diabetes Res Clin Pract
.
2016
;
119
:
106
17
. .
22.
Berggren
EK
,
Boggess
KA
,
Mathew
L
,
Culhane
J
.
First trimester maternal glycated hemoglobin and sex hormone-binding globulin do not predict third trimester glucose intolerance of pregnancy
.
Reprod Sci
.
2017
;
24
(
4
):
613
8
. .
23.
Khambule
L
,
George
JA
.
The role of inflammation in the development of GDM and the use of markers of inflammation in GDM screening
.
Adv Exp Med Biol
.
2019
;
1134
:
217
42
. .
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.